Skip to main content

Table 2 Rheumatoid arthritis and cardiovascular disease related variables per DMARD-group including associated p values

From: Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study

Groups n (percent) RA related variables (p value) CVD related risk factors (p value)
   RA duration Percentage RF Percentage erosive Percentage hypertension Percentage diabetes Percentage hypercholesterolemia
Entire group 613 (100) 9 72 82 22 6 4
Never MTX, SSZ or HCQ 37 (6) 12 (0.25) 68 (0.58) 70 (0.06) 24 (0.74) 11 (0.19) 10 (0.11)
Only MTX ever 51 (8) 5 (<0.001)a 61 (0.09) 57 (<0.001)a 12 (0.06) 16 (0.002)a 6 (0.77)
Only SSZ ever 82 (13) 8 (0.29) 70 (0.65) 73 (0.03)a 26 (0.38) 2 (0.16) 9 (0.14)
Only HCQ ever 36 (6) 12 (0.01)a 70 (0.77) 81 (0.85) 17 (0.46) 3 (0.42) 4 (0.96)
MTX and SSZ ever 199 (33) 9 (0.10) 75 (0.18) 85 (0.12) 22 (0.97) 6 (0.80) 1 (0.11)
MTX and HCQ ever 20 (3) 10 (0.83) 75 (0.73) 80 (0.12) 22 (0.97) 6 (0.80) 1 (0.11)
SSZ and HCQ ever 39 (7) 10 (0.39) 69 (0.74) 90 (0.20) 39 (<0.001)a 3 (0.36) 0 (0.35)
MTX, SSZ and HCQ ever 149 (24) 10 (0.04)a 73 (0.63) 91 (<0.001)a 20 (0.56) 5 (0.48) 5 (0.90)
  1. Comparison calculated using a Students' t-tests or Pearson's Chi-square tests, relative to the remainder of the population. aSignificant. 'RA duration' is in years; 'Percentage RF' refers to positive test for IgM rheumatoid factor; 'Percentage erosive' refers to erosions on radiographs of hands and/or feet. CVD, cardiovascular disease; DMARD, disease modifying anti-rheumatic drug; HCQ, hydroxychloroquine; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SSZ, sulfasalazine